eFFECTOR Therapeutics, Inc. (EFTR)
Sector: Biotechnology
Industry: Biotechnology
eFFECTOR Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 0.0002 | 0.0002 | 0.0002 | 0.0002 | 712 |
| Nov 5, 2026 | 0.0008 | 0.0008 | 0.0008 | 0.0008 | 277 |
| Oct 28, 2026 | 0.0002 | 0.0002 | 0.0002 | 0.0002 | 300 |
| Oct 22, 2026 | 0.0008 | 0.0008 | 0.0008 | 0.0008 | 500 |
| Oct 20, 2026 | 0.0002 | 0.0002 | 0.0002 | 0.0002 | 119 |
| Oct 6, 2026 | 0.0008 | 0.0008 | 0.0002 | 0.0002 | 1,700 |
| Oct 5, 2026 | 0.0008 | 0.0008 | 0.0008 | 0.0008 | 378 |
| Name | Shares | % | Source |
|---|---|---|---|
13-5315170 · may incl. warrants· stale · filed Feb 2024 | 89.8K | 3.5% | 13G |
PROATHLETE WEALTH MANAGEMENT LLC | 12 | -- | 13F |
Top institutional holders
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers.
The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.
based on 4.71M shares outstanding
30d Avg
382
60d Avg
1.19K
90d Avg
9.53K
eFFECTOR Therapeutics, Inc. (OTC: EFTR) traded at $0.0002 on Nov 16, 2026. 52-week range: $0.0002 to $0.0010. The company is in the Healthcare sector (Biotechnology).